Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus.

About 8 in 10 infants received respiratory syncytial virus protection during the 2023 to 2024 season, according to study findings.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

据外媒新闻，美国FDA要求辉瑞和葛兰素史克（GSK）生产的呼吸道合胞病毒（RSV）疫苗须在标签上增加有关罹患吉兰-巴雷综合征（GBS）风险的警告。吉兰-巴雷综合征是一种罕见的神经系统疾病，其病因可能与感染和免疫反应有关，特征性症状为对称性的肢体无力、 ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

The best way to protect yourself from the flu and COVID is to get vaccinated. This can reduce your chances of getting sick ...